Product Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

CAS:916420-27-4
Molecular Formula:C12H15Cl2N3O2
Purity:95%+
Catalog Number:CM104183
Molecular Weight:304.17

Packing Unit Available Stock Price($) Quantity
CM104183-5g in stock ǕȀ
CM104183-10g in stock ƞźƞ
CM104183-25g in stock ǯŔǯ
CM104183-100g in stock ŭňƻ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:916420-27-4
Molecular Formula:C12H15Cl2N3O2
Melting Point:-
Smiles Code:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1
Density:
Catalog Number:CM104183
Molecular Weight:304.17
Boiling Point:
MDL No:MFCD09025732
Storage:

Category Infos

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products